Literature DB >> 20669233

Selected control events and reporting odds ratio in signal detection methodology.

Nobuhiro Ooba1, Kiyoshi Kubota.   

Abstract

PURPOSE: To know whether the reporting odds ratio (ROR) using "control events" can detect signals hidden behind striking reports on one or more particular events.
METHODS: We used data of 956 drug use investigations (DUIs) conducted between 1970 and 1998 in Japan and domestic spontaneous reports (SRs) between 1998 and 2008. The event terms in DUIs were converted to the preferred terms in Medical Dictionary for Regulatory Activities (MedDRA). We calculated the incidence proportion for various events and selected 20 "control events" with a relatively constant incidence proportion across DUIs and also reported regularly to the spontaneous reporting system. A "signal" was generated for the drug-event combination when the lower limit of 95% confidence interval of the ROR exceeded 1. We also compared the ROR in SRs with the RR in DUIs.
RESULTS: The "control events" accounted for 18.2% of all reports. The ROR using "control events" may detect some hidden signals for a drug with the proportion of "control events" lower than the average. The median of the ratios of the ROR using "control events" to RR was around the unity indicating that "control events" roughly represented the exposure distribution though the range of the ratios was so diverse that the individual ROR might not be regarded as the estimate of RR.
CONCLUSIONS: The use of the ROR with "control events" may give an adjunctive to the traditional signal detection methods to find a signal hidden behind some major events.
Copyright © 2010 John Wiley & Sons, Ltd.

Mesh:

Year:  2010        PMID: 20669233     DOI: 10.1002/pds.2014

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  17 in total

1.  When to publish measures of disproportionality derived from spontaneous reporting databases?

Authors:  Anthonius de Boer
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

2.  Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.

Authors:  Jiao-Jiao Chen; Xue-Chen Huo; Shao-Xia Wang; Fei Wang; Quan Zhao
Journal:  Int J Clin Pharm       Date:  2022-09-30

3.  Hemorrhage Risk Profiles among Different Antithrombotic Regimens: Evidence from a Real-World Analysis of Postmarketing Surveillance Data.

Authors:  Xue Sun; Bi Ze; Ling-Jun Zhang; Yang-Zhong BaiMa; Wei Zuo; Bin Zhao; Luo-Bo GeSang
Journal:  Cardiovasc Drugs Ther       Date:  2020-11-23       Impact factor: 3.727

4.  Development and Application of an Alert System to Detect Cases of Food Poisoning in Japan.

Authors:  Akie Maeyashiki; Manabu Akahane; Hiroaki Sugiura; Yasushi Ohkusa; Nobuhiko Okabe; Tomoaki Imamura
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

5.  Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement.

Authors:  Maximilian Gahr; Bernhard J Connemann; Carlos Schönfeldt-Lecuona; René Zeiss
Journal:  Int J Mol Sci       Date:  2017-01-05       Impact factor: 5.923

6.  Kidney Injury Following Ibuprofen and Acetaminophen: A Real-World Analysis of Post-Marketing Surveillance Data.

Authors:  Qi-Hui Shao; Xue-Dong Yin; Hong-Xia Liu; Bin Zhao; Jian-Quan Huang; Zhi-Ling Li
Journal:  Front Pharmacol       Date:  2021-12-22       Impact factor: 5.810

7.  Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

Authors:  Sainan Bian; Lisha Li; Zixi Wang; Le Cui; Yingyang Xu; Kai Guan; Bin Zhao; Lianglu Wang; Jia Yin
Journal:  World Allergy Organ J       Date:  2021-10-01       Impact factor: 4.084

8.  Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.

Authors:  Lisha Li; Zixi Wang; Le Cui; Yingyang Xu; Kai Guan; Bin Zhao
Journal:  Clin Transl Allergy       Date:  2021-06-03       Impact factor: 5.871

9.  Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.

Authors:  Yang Hu; Ziyu Bai; Yan Tang; Rongji Liu; Bin Zhao; Jian Gong; Dan Mei
Journal:  J Diabetes Res       Date:  2020-07-08       Impact factor: 4.011

10.  Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study.

Authors:  Bin Zhao; Juan Shen; Jun Zhao; Hui Pan
Journal:  J Diabetes Investig       Date:  2021-01-17       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.